Beacon is delighted after launching Multiple Tyrosine Kinase Inhibitor (TKI), Pazonix that is only for the treatment of renal cell carcinoma


Beacon Medicare Limited, a number one oncology company in Bangladesh, has launched Pazonix in tablet form under the generic of Pazopanib, an anti-cancer drug, only for export purpose in the world market.

Pazonix ( pazopanib) is one of the most advanced & latest drug for the treatment of Renal Cell Carcinoma. This is the global first generic of Pazopanib in the world.

The medicine will be available in two strengths 200mg and 400mg --tablet and 30 and 60 tablets will contain both the packets respectively.

Pazonix (Pazopanib 200mg and 400mg) is a multiple Tyrosine Kinase Inhibitor (TKI) and it is indicated for the treatment of renal cell carcinoma effectively.

After a successful launching of the product Beacon authority hoped and believed that the anti-cancer product will enlarge the range of product the company and at the same time, it will be able to earn extra reputation and sales from the global market for the betterment of the company.